CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and
Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer. The
investigators expect to see an increase in response rate of the combination over Anti-CTLA-4
alone and estimate a response rate of approximately 20 % in the proposed population.